Immunotherapy in multiple myeloma using cancer-testis antigens
Iranian Journal of Cancer Prevention. 2015; 8 (5): 11-20
in English
| IMEMR
| ID: emr-175775
ABSTRACT
Context Multiple myeloma [MM] is a B-cell malignancy characterized by monoclonal expansion of abnormal plasma cells in the bone marrow. It accounts for 10% of hematological malignancies. Although patients respond to a wide range of anticancer modalities, relapse occurs in a significant number of the cases. Immunotherapeutic approaches have been evolved to tackle this problem. Cancer-testis antigens CTAs as a group of tumor-associated antigens are appropriate targets for cancer immunotherapy as they have restricted expression pattern in normal tissues except for testis which is an immune-privileged site. Expression of these antigens has been assessed in different malignancies including MM
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Testicular Neoplasms
/
Neoplastic Stem Cells
/
Biomarkers, Tumor
/
Immunotherapy
/
Antigens, Neoplasm
Limits:
Humans
Language:
English
Journal:
Iran. J. Cancer Prevention
Year:
2015
Similar
MEDLINE
...
LILACS
LIS